Substantial data has accumulated showing that antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF) or VEGF receptor-2 (VEGFR-2) can modulate the tumor immunosuppressive microenvironment and might help to reverse resistance to immunotherapy (12–14). A translational study, in Colon-26 adenocarcinoma model, shows that simultaneous blockade of PD-1 and VEGFR enhance ICI-induced effects such as reinforcement of antigen presentation and increase of T cells infiltration (15). This evidence concerns the gene KDR and adenocarcinoma.